Brief: Inozyme Pharma Announces First Self-Administration Of INZ-701 In Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial
03/11/2022 11:42
Nov 3 (Reuters) - Inozyme Pharma Inc INZY.O :
* INOZYME PHARMA ANNOUNCES FIRST SELF-ADMINISTRATION OF
INZ-701 IN
ONGOING ENPP1 DEFICIENCY PHASE 1/2 CLINICAL TRIAL
Source text for Eikon: ID:nGNX2QfhjG
Further company coverage: INZY.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Inozyme Pharma
See all newsBrief: Inozyme Pharma postpones 2025 annual meeting of stockholders
U.S. RESEARCH ROUNDUP-Advansix, Cognizant, Inozyme Pharma
U.S. STOCKS ON THE MOVE-Netflix, Acadia Pharma, CoreWeave
U.S. STOCKS ON THE MOVE-Inozyme Pharma, Emerson Electric, Stanley Black & Decker
Inozyme Pharma rises over 175% on $270 million buyout deal with BioMarin